Gilead is loosening its TIGIT partnership with Arcus after the Phase 3 domvanalimab study failed on its futility assessment, triggering trial culls and a broader renegotiation of options. Gilead’s access to certain early-stage Arcus programs ends as the partners step away from additional development under the collaboration timeline.